179463-17-3

Basic information

• Product Name: Cancidas
• Synonyms: Caspofungin acetate;(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-Aminoethylamino)-3-[3-amino-1(R)-hydroxypropyl]-6-[1(S),2(S)-dihydroxy-2-(4-hydroxyphenyl)ethyl]-18-(10,12-dimethyltetradecanamido)-11,20,25-trihydroxy-15-[1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate;Cancidas;L 743,872;L 743872;L-743,872;L-743872;Mk 0991
• CAS NO: 179463-17-3
• Molecular Formula: C52H88N10O15.2(C2H4O2)
• Molecular Weight: 1213.42
• EINECS: 1592732-453-0
• Product Categories: Amines;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API
• Mol File: 179463-17-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 1501.4 °C at 760 mmHg
• Flash Point: 861.8 °C
• Appearance: white to beige/
• Vapor Pressure: 0mmHg at 25°C
• Storage Temp.: ?20°C
• Solubility: H2O: soluble15mg/mL (clear solution)
• CAS DataBase Reference: Cancidas(CAS DataBase Reference)
• NIST Chemistry Reference: Cancidas(179463-17-3)
• EPA Substance Registry System: Cancidas(179463-17-3)

Safety Data

• WGK Germany: 3
• RTECS: TP8046500
• Hazardous Substances Data: 179463-17-3(Hazardous Substances Data)

Usage

Description

Cancidas, also known as Caspofungin, is an antifungal compound belonging to the echinocandin class. It is a water-soluble, stable, aza-substituted semisynthetic derivative of pneumocandin B, a fermentation product of the fungus Zalerion arboricola. Cancidas acts by noncompetitively inhibiting the enzyme 1,3-β glucan synthase, which prevents the synthesis of glucan in the fungal cell wall. This leads to the specific lysis of pathogenic fungal cells, making it fungicidal rather than fungistatic. Cancidas is effective against a range of Candida species, including those resistant to azole and amphotericin B, as well as against Aspergillus, an important pathogen not susceptible to fluconazole.

Uses

Used in Pharmaceutical Industry:
Cancidas is used as an antifungal agent for the treatment of invasive fungal infections, particularly in patients who are refractory to or intolerant of other antifungal therapies such as amphotericin-B1 lipid formulation of amphotericin-B and/or itraconazole. It is effective against a range of Candida species and Aspergillus, an important pathogen not susceptible to fluconazole.
Used in Medical Treatment:
Cancidas is used as a treatment for invasive aspergillosis and candidiasis in patients who have not responded well to other antifungal medications. It has a half-life in humans of around 10 hours and does not inhibit cytochrome P450, making it a safer option for patients with specific medical conditions.
Used in Research and Development:
Cancidas is used in research and development for the study of fungal cell wall synthesis and the development of new antifungal agents. Its unique mechanism of action and effectiveness against resistant strains make it a valuable tool in the fight against invasive fungal infections.

Biochem/physiol Actions

Caspofungin is an echinocandin antifungal that inhibits 1,3-β-D-glucan synthase, which is required for cell wall synthesis, thereby disturbing the integrity of the fungal cell wall.

Veterinary Drugs and Treatments

Caspofungin has potential for treating invasive aspergillosis or disseminated candidal infections in companion animals although little, if any, information on its use in dogs or cats is available.

InChI:InChI=1/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28?,29?,30-,33-,34-,35+,36-,37+,38-,40+,41+,42+,43?,44+,45+,46+;;/m1../s1

Upstream product

• 57260-73-8 N-BOC-1,2-diaminoethane 
• 75-36-5 acetyl chloride 
• 64-19-7 acetic acid 
• 107-15-3 ethylenediamine 
• 935732-69-7 C₅₆H₈₃BN₈O₁₇ 
• 936000-60-1 C₅₆H₈₄N₈O₁₆S 
• 150283-04-8 10,12-dimethyl-tetradecanoic acid [3-(3-amino-1-hydroxy-propyl)-6-[1,2-dihydroxy-2-(4-hydroxy-phenyl)-ethyl]-11,20,21,25-tetrahydroxy-15-(1-hydroxy-ethyl)-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaaza-tricyclo[22.3.0.0^9,13]heptacos-18-yl]-amide 
• 1230487-11-2 C₅₇H₈₈N₈O₁₅S 

Relevant articles and documents

CASPOFUNGIN ANALOG AND APPLICATIONS THEREOF

Disclosed are a caspofungin analog and applications thereof. Said caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable slats thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R 2 , R 3 , R 4 , R 5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of said compound.

PROCESS FOR PREPARING CASPOFUNGIN AND NOVEL INTERMEDIATES THEREOF

The present invention relates to a novel process for preparing the aza cyclohexapeptide compound 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 (caspofungin), which can improve the problem due to a pungent odor and toxicity during the process and can prepare caspofungin as a final product at high yield compared to conventional processes, and to novel intermediates which are used in the preparation process.

Caspofungin free of caspofungin Co

The present invention provides Caspofungin and salts thereof substantially free of Caspofungin C0 and salts thereof. The present invention also provides processes for the preparation of said Caspofungin and salts thereof and processes for the d